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Background {#sec005}
==========

*Neisseria gonorrhoeae* (gonococcus) is the second most common etiologic agent known to cause sexually transmitted infection (STI) with a significant global public health impact \[[@pone.0233753.ref001]\]. In uncomplicated infections, the disease manifests as urethritis in men and mucopurulent cervicitis in women. Because gonococcal infections are often asymptomatic in women, the lack of noticeable symptoms may result in serious complications such as pelvic inflammatory disease, ectopic pregnancy, and infertility. Infants born to a mother with the infection could develop conjunctivitis which may eventually lead to blindness if the infection is left untreated. In men, if left untreated, the disease could result in problems such as epididymitis, urethral stricture, and infertility. The transmission of the disease occurs by direct contact with secretions of infected mucosal surfaces and the incubation period can range from 1 to 10 days \[[@pone.0233753.ref001]\]. Gonorrhea, as with any STI, can work as a gateway to HIV and other infections \[[@pone.0233753.ref002], [@pone.0233753.ref003]\]. Globally, more than millions of people are affected by curable STIs. According to WHO, in 2012 alone, globally, there were an estimated 78 million new case of gonococcal diseases \[[@pone.0233753.ref001]\]. Public health control of gonorrhea requires both treatment of patients with appropriate antimicrobials as well as generalized and targeted prevention efforts \[[@pone.0233753.ref001], [@pone.0233753.ref004], [@pone.0233753.ref005]\].

Treatment regimens for gonorrhea have been changed frequently over the past few decades due to the organism's propensity for developing antibiotic resistance \[[@pone.0233753.ref001]\]. Over the past few years, gonococcus have become less susceptible to previously used antibiotics such as ciprofloxacin or tetracycline \[[@pone.0233753.ref001]\]. Until recently, quinolones have been used as an alternative to treat gonococcal infections. However, the emergence and spread of gonococci resistant to the quinolone group and reduced susceptibility to third generation cephalosporin antibacterial was reported from different corners of the world \[[@pone.0233753.ref001]\]. This trend is concerning considering no alternative antibiotic treatment options or combinations have been proven to be effective against the organism \[[@pone.0233753.ref006]--[@pone.0233753.ref010]\].

The treatment for gonococcal infection in sub-Saharan Africa countries, including Ethiopia, is based on a syndromic approach using single dose fluoroquinolone treatment. The basis for this regimen was under the assumption that resistance to fluoroquinolones is considered to be low in Africa. However, with the occurrence of resistance to commonly prescribed antibiotics in both developed and developing countries, it is imperative to investigate the resistance pattern of gonococcal isolates periodically. Therefore, updated knowledge of the prevailing susceptibility patterns of gonococcal isolates in Ethiopia is important for the proper selection and use of antimicrobial drugs as well as for the development of an appropriate prescription policy. Therefore, this study aimed to investigate the susceptibility patterns of quinolones and third-generation cephalosporin found in *N*. *gonorrhoeae* isolated from urethral discharge of male patients seen in selected Addis Ababa city health centers.

Methods {#sec006}
=======

Study sites and design {#sec007}
----------------------

This study was conducted within the Addis Ababa, Ethiopia City Administration. Addis Ababa, the capital city of the Democratic Republic of Ethiopia, is geographically located in the central part of the country. A cross-sectional, facility-based study was conducted in eight healthcare centers of Addis Ababa. The selected healthcare facilities consisted of the *Arada*, *Tekalehaimanot*, *Addis-Ketema*, *Kirkos*, *Kotebe*, *Akaki-Kaliti*, *Shiromeda*, and *Kassanchis* health centers. These healthcare facilities were selected based on a high flow of STI patients determined from a previous assessment. The study team collected samples from visiting patients over a span of twelve months at each study site following training on study protocols, procedures, and research ethics.

Source population and study participants {#sec008}
----------------------------------------

The source population consisted of patients visiting the selected healthcare facilities within Addis Ababa, Ethiopia with symptoms of urethral discharge who also gave consent to participate in the study. All urethral discharge specimens analyzed between August 2013 and August 2014 were included in this study.

Laboratory methods {#sec009}
------------------

### Specimen collection {#sec010}

Men presenting to the selected healthcare facilities with urethral discharge syndrome were recruited in the study following their consent. Afterward, a sterile Dacron swab-tipped applicator was used to collect urethral secretions. The swabs were then inoculated on Modified Thayer Martin Agar plates made of Gonococcal agar base supplemented with isovitalex (vitox); vancomycin, colistin, nystatin, and trimethoprim (VCNT); and synthetic hemoglobin (Oxoid and BBL) prepared in-house. The inoculated plates were incubated on site using a candle jar and then transported to the Ethiopian Public Health Institute (EPHI), Clinical Bacteriology and Mycology Reference Laboratory within the same day of collection. Swabs were rolled onto a microscopy slide, labeled, heat fixed, placed in a slide box, and sent to EPHI for Gram-stain analysis.

### Culture and identification {#sec011}

In the clinical bacteriology laboratory at EPHI, inoculated plates were incubated at 35°C in a carbon dioxide enriched environment (5--8% CO2) for 72-hours. Plates were inspected every day for the growth of small, translucent, and non-pigmented colonies. Plates that were gram-negative, diplococcic, convex, glistening, elevated, had mucoid colony characteristics, and were oxidase, catalase, and supercool (30% H2O2) positive were considered as probable *N*. *gonorrhoeae* and further confirmed by carbohydrate and enzymatic tests using API-NH^R^. Antimicrobial susceptibility testing was performed by the Kirby-Bauer disc diffusion method using ciprofloxacin (5 μg), ceftriaxone (30 μg), cefixime (30 μg), cefoxitin (30 μg), penicillin (10 μg) and spectinomycin (100 μg) on enriched GC agar (Oxoid Ltd) plus 1% BBL Isovitalex Enrichment. Minimum Inhibitory Concentration (MIC) was done using concentration gradient strips (E-test) of the same antibiotics. The range of inhibition zones and MIC for each type of antibiotic disk were interpreted according to Clinical Laboratory Standard Institute (CLSI) guidelines \[[@pone.0233753.ref011]\]. *Neisseria gonorrhoeae* reference strain ATCC 49226 was used as a positive control.

Data extraction methods {#sec012}
-----------------------

A structured checklist was used to collect information on socio-demographics, clinical history, sexual behaviors, pro-antibiotics taken, and laboratory data such as the antibiotic susceptibility results. All data were double entered to Cespro 8 software by two individuals and data analysis was done using SPSS version 20.

Operational definitions {#sec013}
-----------------------

Non-susceptible *N*. *gonorrhoeae* isolates were defined as those that are not sensitive to the antibiotic tested for susceptibility, i.e., those isolates exhibiting resistance or intermediate resistance.

Dual non-susceptibility was defined as lack of susceptibility to any two of the antibiotics tested for susceptibility. Multi Drug Non-susceptibility was defined as combined non-susceptibility to an injectable cephalosporin and any two of either quinolones, penicillins, or tetracyclines.

Ethics and consent to participate {#sec014}
---------------------------------

This study was ethically cleared by the Scientific and Ethical Review Office (SERO) of the Ethiopian Public Health Institute and the Institutional Review Board (IRB) of CDC-Atlanta. At the enrollment visit, all men with urethral discharge provided written consent after being diagnosed according to the syndromic treatment guidelines approved in Ethiopia. Those who were eligible (\> 18 years of age) and willing to participate in the study were recruited using a structured questionnaire for their demographic and behavioral data. All data were kept confidential and anonymous. Brief counseling on the importance of adherence to STI medications, not having sex while taking medications, HIV/STI prevention, and recommendations to use condoms to reduce STI/HIV acquisition and transmission was also given.

Results and discussion {#sec015}
======================

Between August 2013 and August 2014, a total of 599 urethral discharge specimens were collected from male patients visiting one of the eight selected healthcare centers for routine clinical care and the collected specimens were microbiologically analyzed. The mean age of the study participants was 27 years (SD ± 7.2), with all being male. Observation of the urethral discharge specimens revealed that over 90% of them were profuse/thick discharge ([Table 1](#pone.0233753.t001){ref-type="table"}).

10.1371/journal.pone.0233753.t001

###### Clinical presentations of urethral discharge from patients visiting health centers in Addis Ababa.

![](pone.0233753.t001){#pone.0233753.t001g}

  Clinical feature                   Category        N (%)
  ---------------------------------- --------------- ------------
  **Fluid coming out of penis**      Yes             597(99.7)
  No                                 2 (0.3)         
  Total                              599 (100)       
  **Nature of Urethral discharge**   Profuse/Thick   547 (91.3)
  Watery                             44 (7.3)        
  Other                              8 (1.3)         
  Total                              599 (100)       

Proportion of gonococcal isolates recovered {#sec016}
-------------------------------------------

Of all the specimens analyzed, 415 (69.3%) gonococcal isolates were identified through culture methods. Compared to culture, the proportion of presumptive gonorrhea-positive samples was higher (75%) by gram stain ([Table 2](#pone.0233753.t002){ref-type="table"}). This is not surprising as considerable proportion of the patients (20%) were on antibiotics when the specimens were collected which would affect culture results ([Table 3](#pone.0233753.t003){ref-type="table"}). The prevalence of gonococcus in this study was relatively higher than other studies conducted in Ethiopia \[[@pone.0233753.ref012]--[@pone.0233753.ref014]\]. The difference may be due to the nature of the participants in the current study considering all of them were males and also showing clinical manifestation of the disease. The general notion is that naturally, males tend to be more symptomatic for gonococcal infection and hence can have increased level of healthcare seeking behavior which in turn makes them statistically overrepresented \[[@pone.0233753.ref015]\].

10.1371/journal.pone.0233753.t002

###### Comparison of gram stains and culture methods for the detection of gonococcus isolates from urethral discharge specimens.

![](pone.0233753.t002){#pone.0233753.t002g}

  GC confirmation method   Result     N (%)
  ------------------------ ---------- -----------
  Gram stain               Positive   449 (75)
                           Negative   150 (25)
  Total                               599(100)
  Culture                  Positive   415 (69)
                           Negative   184 (31)
  Total                               599 (100)

10.1371/journal.pone.0233753.t003

###### Medical treatment history of patients with urethral discharge from health centers in Addis Ababa, August 2013--August 2014.

![](pone.0233753.t003){#pone.0233753.t003g}

  Medication history            Response     N (%)
  ----------------------------- ------------ ------------
  Taking medication             Yes          123 (20.5)
  No                            476 (79.5)   
  Total                         599 (100)    
  Know the type of medication   Yes          107 (87)
  No                            16 (13)      
  Total                         123 (100)    
  Ciprofloxacin                 Yes          91 (85)
  No                            16 (15)      
  Total                         107 (100)    
  Doxycycline                   Yes          93 (86.9)
  No                            14 (13.1)    
  Total                         107 (100)    
  Metronidazole                 Yes          12 (11.2)
  No                            95 (88.8)    
  Total                         107 (100)    

Antimicrobial resistance profile {#sec017}
--------------------------------

In sub-Saharan Africa, gonococcal treatment practice is based on a syndromic approach using a single dose fluoroquinolone treatment. It is hypothesized that resistance to fluoroquinolones is low in Africa, but there has been limited systematic data collection and analysis to verify this notion. A multicounty antimicrobial resistance study on gonococcal strains isolated in 2004--2006 indicated low rates of fluoroquinolone resistance with 0%, 1.3% and 4.0% in the Central African Republic, Cameroon, and Madagascar, respectively \[[@pone.0233753.ref016]\]. Similarly, a study conducted in Maputo and Mozambique in 2005 suggested that there was no resistance to fluoroquinolone by gonococcal isolates \[[@pone.0233753.ref017]\].

In contrast, the findings from several other countries in sub-Saharan Africa suggested increasing levels of fluoroquinolone resistance in gonococcal isolates. According to a study done in South Africa in 2004, 7% of the gonococcal isolates from the Pretoria region, 8% from the Western Cape, and 17% from Johannesburg were found to be resistant to antibiotics from the class of fluoroquinolone. In addition, another study conducted in same country and the same study populations in 2007 indicated that 27% of the gonococcal isolates from Cape Town and 32% of isolates from Johannesburg were found to be resistant to ciprofloxacin \[[@pone.0233753.ref018]\]. This represents a 2.9 fold and 1.9 fold increases, respectively, within a 3-year time period. Similarly, a two-year prospective study carried out among STI patients from 2004 to 2006 in Johannesburg indicated an increase in ciprofloxacin resistance from 13% in the first year to 26.3% in the second year \[[@pone.0233753.ref019]\]. Another study conducted in Kenya and Uganda also showed that gonococcal resistance level to fluoroquinolone has reached up to 53% and 83%, respectively \[[@pone.0233753.ref020], [@pone.0233753.ref021]\].

The present study has revealed that *N*. *gonorrhoeae* isolates recovered from urethral discharge of male patients in Addis Ababa, Ethiopia have shown a high level of resistance to the commonly prescribed fluoroquinolone class of antibiotics in Ethiopia (60%). This finding is in agreement with other studies which reported resistance levels between 53% and 83% in the East African region including Kenya and Uganda. Reports from South Africa also indicate that the resistance level has reached up to 32% \[[@pone.0233753.ref019]--[@pone.0233753.ref022]\]. The proportion of ciprofloxacin-resistant gonococcal isolates in the United States has also reached more than 30% \[[@pone.0233753.ref003]\]. The high proportion of quinolone resistance in this study might be due to prior treatment using ciprofloxacin, as indicated in [Table 3](#pone.0233753.t003){ref-type="table"}. Gonococcal syndromic treatment using oral fluoroquinolone has become very problematic due to the emergence of a high proportion of resistant isolates, as witnessed from the current study. The good news, however, is that non-susceptibility to ceftriaxone has not been detected in any of the isolates tested during the study period. This finding is not in agreement with other studies conducted in different part of Ethiopia \[[@pone.0233753.ref012]--[@pone.0233753.ref014]\]. This may be due to exposure of participants to a specific group of antimicrobial agents during the study period. However, our finding was in agreement with studies conducted elsewhere \[[@pone.0233753.ref023]--[@pone.0233753.ref027]\]. As indicated in [Fig 1](#pone.0233753.g001){ref-type="fig"}, majority of the isolates have shown MIC value of 0.016 μg/ml for ceftriaxone with all of them having MIC values well below the cut-off point (0.25 μg/ml). However, the existence of certain segments of the isolate population with MIC values close to the cut-off point may indicate potential for a minority non-susceptible bacterial population to potentially replace the susceptible majority population. Therefore, investigating the molecular mechanism of resistance in these group of isolates may be imperative to fully understand the epidemiology \[[@pone.0233753.ref026]\].

![Minimum Inhibitory Concentration (MIC) of ceftriaxone against *N*. *gonorrhoeae*.](pone.0233753.g001){#pone.0233753.g001}

The figure shows the MIC levels of ceftriaxone for gonococcal isolates recovered from urethral discharge specimens that were collected from male patients. All of the isolates tested using concentration gradient strips (E-test) were well below the cut-off point (0.25 μg/ml) for ceftriaxone MIC, with majority of them having MIC value of 0.016 μg/ml and none of them being non-susceptible. A small proportion of the isolates had MIC value at the cut-off point.

In our study, the Penicillinase test was carried out by a chromogenic test showing almost more than half of the isolates to be positive for beta lactamase. Most of the isolates in the current study were resistant to Benzyl penicillin even though the antibiotic is not used for the national gonococcal treatment algorithm ([Table 4](#pone.0233753.t004){ref-type="table"}). This finding from our study was also in line with other studies \[[@pone.0233753.ref024], [@pone.0233753.ref025], [@pone.0233753.ref027]--[@pone.0233753.ref029]\].

10.1371/journal.pone.0233753.t004

###### Percent of antimicrobial susceptibility pattern of gonococcal isolates recovered from urethral discharge of patients (N = 361).

![](pone.0233753.t004){#pone.0233753.t004g}

  Antimicrobial agent   Class             Susceptibility profile                            
  --------------------- ----------------- ------------------------ ---------- ------------- ---------
  P                     Penicillins       191(52.9)                0(0)       170 (47.1)    \-
  Sp                    Aminocyclitols    11 (3)                   4 (1.1)    346 (95.9)    \-
  Cip                   Flouroquinolone   217 (60.2)               26 (7.1)   118 (32. 7)   \-
  CRO                   Cephalosposrin    0 (0)                    0(0)       361 (100)     \-
  CFX                   Cephalosposrin    \-                       0(0)       307 (85)      54 (15)
  CTX                   Cephalosporin     4 (1.1)                  0(0)       357 (98.9)    \-
  AZ                    Macrolides        36 (10)                  0(0)       325 (90)      \-

AZ = Azithromycin, CIP = Ciprofloxacin, CFX = Cefixime, CRO = Ceftriaxone, CTX = Cefoxitin, P = Penicilin, SP = Spectinomycin.

According to WHO, dual therapy is the preferred option for treatment of gonococcal infection instead of single therapy \[[@pone.0233753.ref001]\]. In the present study, non-susceptibility for the combination of ciprofloxacin and penicillin was observed at a rate of 6.9% (25/361), while for ciprofloxacin and spectinomycin were at a rate of 0.8% (3/361). Institutionalizing a surveillance system in the country might help track the resistance level of the isolates.

Formerly, the STI treatment practice in Ethiopia was based on the syndromic approach (treating individuals immediately for possible causes of STI syndromes based on symptom). The syndromic treatment guideline was produced in 2006 and has been in use for years \[[@pone.0233753.ref010]\]. However, because of the findings from this study and other studies in the country, the national guideline for treatment has been changed \[[@pone.0233753.ref030]\]. In the former guideline, ciprofloxacin was recommended to treat gonococcal infections because resistance to it was not then documented. The current guideline recommends ceftriaxone instead of ciprofloxacin \[[@pone.0233753.ref030]\]. The etiologic approach to diagnosis of gonorrhea is important, especially for revisiting clients, in order to identify non-susceptible isolates to serve as candidates for antimicrobial agents in practice.

Conclusions {#sec018}
===========

In the current study, the proportion of *N*. *gonorrhoeae* isolates in males with urethral discharge in Addis Ababa, Ethiopia, was found to be high. Of greatest concern was the finding that these gonococcal isolates were highly resistant to the new generation of antibiotics, fluoroquinolones (ciprofloxacin), which has been indicated as the treatment of choice according to previous national guidelines. Results generated from this study were used as input to revise the national syndromic guidelines for management of patients presenting with urethral discharge due to gonorrhea. As a result, ciprofloxacin was replaced by ceftriaxone which was found to be effective in terms of in vitro susceptibility results \[[@pone.0233753.ref030]\]. In conclusion, the syndromic-based diagnostic approach needs to be periodically validated and modified based on determination of susceptibility patterns of *N*. *gonorrhoeae* isolates in the region. Since this study was done in 2014, additional studies are warranted to understand the current antimicrobial resistance status of *gonorrhoeae* isolates in Ethiopia.

Supporting information {#sec019}
======================
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Click here for additional data file.
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PLOS ONE

Dear Mr Dinku,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 08 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

David Gabriel Regan, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The reviewers agree that the revised version of the manuscript is is substantially improved but the language and grammatical issues have not been adequately addressed. It was recommended that the authors seek editorial assistance in addressing these issues and it seems this recommendation has not been taken on board. The reviewers agree that the manuscript is scientifically sound on the whole but the language and presentation is not up to the standard required for publication in PLoS ONE. I feel the authors should have a final opportunity to address the language and presentation issues highlighted by the reviewers but the manuscript will need to be substantially improved for me to be able to recommend publication in PLoS ONE. The authors also need to provide a consistent statement that aligns with PLoS ONE publication policy in regard to availability of data.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript has been considerably improved in both the discussion of content and in the quality of its writing. Unfortunately it still falls well short of the standard expected for a credible scientific journal. There is still a large number of spelling and basic grammatical errors, clearly indicating that a native speaker was not consulted as advised. Other sentences were either badly worded, or too long and needing to be broken into smaller sentences. Examples are the final sentence of the abstract and \"Globally, more than millions of curable STD are affecting people every day\" from the Background section.

The caption for Figure 1 inexplicably appears in isolation in the middle of page nine with no figure. This may be an artifact of separating figures and tables from the main body of the text in the draft copy but the same has not happened for the tables so care must be taken with this.

Table 3 (previously Table 2) is now much clearer but the percentages in the bottom two rows still do not add to 100%. My best guess is that the remaining samples were non-susceptible, but this should be indicated explicitly.

Tables 3 and 4 are referenced out-of-order and their numbering should be reversed.

The y-axis of the figure is labelled \"Proportion of Gonococcal isolates\" but the bars clearly do not add up to 100%. Either it is mislabelled or the scale is wrong. If the axis is a proportion then the ticks should be labelled 20%, 40%, \... , 100% .

The authors are inconsistent in their responses to PLOS ONE\'s data sharing requirement. They have claimed under their Data Availability statement that \"data are fully available without restriction\" and \"included in the manuscript\" and that they \"can give the raw data\", but stated in their response to reviewers that they are restricted from doing so from privacy concerns. I suspect that they do not properly understand this requirement. The PLOS Data policy allows exceptions if the data \"compromise the privacy or confidentiality of human research subjects\" but the de-identification of data in a study such as this has long been standard practice and there is no discussion of these restrictions in the Materials and Methods.

While the scientific core of this work appears to be sound, the manuscript and data-sharing still do not approach the standards expected for a high quality scientific journal. I suggest after attending to these comments that the authors submit their work to a journal more specific to public health.

Reviewer \#2: Thanks to the authors for making the required changes.

Please consider making the following revisions.

1\) Abstract. Please note that gonorrhea is the disease/infection. No need to see gonorrhea disease.

2\) Introduction. Please consider editing the following sentence \"Globally, more than millions of curable STD are

affecting people every day. According to WHO, in 2012 alone, there were an estimated 78 million new

case of gonococcal diseases \[1\].

3\) Introduction: The following section of the introduction could use some editing. \"Over the past few years, gonococcus have

become less susceptible to previously used antibiotics such as sulfonamides or tetracycline. Until recently, quinolones and third-generation cephalosporins are alternative to treat gonococcal infections\". Please note that sulfonamides have not been recently prescribed and that third generation celaphosporins are currently the recommended treatment option.

4\) Methods. STI needs to be spelled out the first time that is used in the document. Overall, this reviewer recommends changing STD to STI.

5\) Methods. The following two sentences are confusing. \"A sterile cotton-tipped swab were used to obtain a swab specimens. Then sterile Dacron swabs tipped applicator were used to collect urethral secretions\". It sounds like two different swabs were used for sample collection.

6\) Operating definitions. Penicillin is mentioned here, but in the methods section it is not clear that the isolates were tested for penicillin susceptibility.

7\) Ehtics and Consent. Please clarify the following sentence. \"At the enrollment visit, all men with urethral discharge (UD) were given written consent diagnosed according to the syndromic treatment guidelines approved in Ethiopia\". It is not clear to this reviewer what \"written consent diagnosed\" means.

8\) Results. This reviewer does not understand the relevance of the following sentence. \"Observation of the specimens revealed that over 90% of them were profuse /thick discharge (Table-1).

9\) Proportion of gonococcal isolates recovered. The sentence \"Compared to culture, the proportion of the identified isolates was higher (75%) when gram stain method was used (Table-2)\" requires editing. It is not possible to isolate NG by gram stain. Please edit sentence as follows \"Compared to culture, the proportion of presumptive gonorrhea-positive samples was higher (75%) by gram stain.

10\) Figure 1 header. Please change N. gonorrhea to N. gonorrhoeae.

11\) Conclusion. Please change gonorrhea disease to gonorrhea.

12\) Conclusion. The authors should add a sentence regarding the limitation of using samples that were collected in 2013-2014. The epidemiology of resistance is probably different now. They can also say that additional studies are warranted to understand the current (2020) epidemiology of antimicrobial resistance in NG in Ethiopia.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Michael Luke Walker

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Response to reviewers:

Dear reviewers, thank you so much.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Response to reviewers:

Dear reviewers, thank you so much.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Response to reviewers:

Dear reviewers, thank you so much. As to the availability of Data, we have requested our institute for de-identifying the data set and are able to share it, as supplement file, during this current submission. Thank you.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

Response to reviewers:

Dear reviewers, thank you. We have tried to address the major issue raised accordingly. We sought an editorial assistance from native English speaker, Dr. Laura Binkley (<binkley.69@osu.edu>) from the Ohio State Unviersity, USA. And we thank Dr. Laura for the English language edits and overall comments that, we believe, has substantially improved the manuscript. We have checked the spelling and over all neatness of the manuscript in as much as we can.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript has been considerably improved in both the discussion of content and in the quality of its writing. Unfortunately it still falls well short of the standard expected for a credible scientific journal. There is still a large number of spelling and basic grammatical errors, clearly indicating that a native speaker was not consulted as advised. Other sentences were either badly worded, or too long and needing to be broken into smaller sentences. Examples are the final sentence of the abstract and \"Globally, more than millions of curable STD are affecting people every day\" from the Background section.

Response to reviewer:

Dear reviewer, thank you for the priceless comments. We have tried to address your comments and have consulted a native English speaker to address the language issues. Thank you once again.

The caption for Figure 1 inexplicably appears in isolation in the middle of page nine with no figure. This may be an artifact of separating figures and tables from the main body of the text in the draft copy but the same has not happened for the tables so care must be taken with this.

Response to reviewer:

Dear reviewer, thank you for the comment; as you rightly put it, it was an artifact left during the process of separating the figure from the main body of the text. We are very sorry for killing your precious time. We have made the correction. We have also tried to check to avoid such mistakes all over the manuscript. Thank you.

Table 3 (previously Table 2) is now much clearer but the percentages in the bottom two rows still do not add to 100%. My best guess is that the remaining samples were non-susceptible, but this should be indicated explicitly. Tables 3 and 4 are referenced out-of-order and their numbering should be reversed.

Response to reviewer:

Dear reviewer, thank you for the comments and positive words. The numbers were simply counted for those sample how have CIP + Spectinomycin combined resistance level. To avoid confusion we have omitted the bottom two rows that do not add up to 100. We have also revised the position of table-3 and 4. Thank you.

The y-axis of the figure is labelled \"Proportion of Gonococcal isolates\" but the bars clearly do not add up to 100%. Either it is mislabelled or the scale is wrong. If the axis is a proportion then the ticks should be labelled 20%, 40%, \... , 100% .

Response to reviewer:

Thank you. Y-axis is proportion but we did not indicate in percentage. We have corrected this by adding % on the y-axis label.

The authors are inconsistent in their responses to PLOS ONE\'s data sharing requirement. They have claimed under their Data Availability statement that \"data are fully available without restriction\" and \"included in the manuscript\" and that they \"can give the raw data\", but stated in their response to reviewers that they are restricted from doing so from privacy concerns. I suspect that they do not properly understand this requirement. The PLOS Data policy allows exceptions if the data \"compromise the privacy or confidentiality of human research subjects\" but the de-identification of data in a study such as this has long been standard practice and there is no discussion of these restrictions in the Materials and Methods.

Response to reviewer:

Dear Reviewer, You are right we did not fully understood the policy but after the comments, this issue has been addressed by provision of the de-identified data set as a supplement file with this submission.

While the scientific core of this work appears to be sound, the manuscript and data-sharing still do not approach the standards expected for a high quality scientific journal. I suggest after attending to these comments that the authors submit their work to a journal more specific to public health.

Response to reviewers:

Dear reviewer, thank you so much for the very constructive comments you gave us and definitely that have significantly improved our manuscript in terms of language usage and data presentation. Thank you for your precious time and patience in reviewing our manuscript.

Reviewer \#2: Thanks to the authors for making the required changes.

Please consider making the following revisions.

1\) Abstract. Please note that gonorrhea is the disease/infection. No need to see gonorrhea disease.

Response to reviewers:

Dear reviewer, thank you so much for the very constructive comments. The correction have been made as per the comment.

2\) Introduction. Please consider editing the following sentence \"Globally, more than millions of curable STD are

affecting people every day. According to WHO, in 2012 alone, there were an estimated 78 million new

case of gonococcal diseases \[1\].

Response to reviewers:

Dear reviewer, thank you so much for the comments. The correction have been made as per the comment.

3\) Introduction: The following section of the introduction could use some editing. \"Over the past few years, gonococcus have

become less susceptible to previously used antibiotics such as sulfonamides or tetracycline. Until recently, quinolones and third-generation cephalosporins are alternative to treat gonococcal infections\". Please note that sulfonamides have not been recently prescribed and that third generation celaphosporins are currently the recommended treatment option.

Response to reviewers:

Dear reviewer, thank you so much for the comments. The correction have been made as per the comment.

4\) Methods. STI needs to be spelled out the first time that is used in the document. Overall, this reviewer recommends changing STD to STI.

Response to reviewers:

Dear reviewer, thank you so much for the comments. The correction have been made as per the comment. And STD was replaced with STI.

5\) Methods. The following two sentences are confusing. \"A sterile cotton-tipped swab were used to obtain a swab specimens. Then sterile Dacron swabs tipped applicator were used to collect urethral secretions\". It sounds like two different swabs were used for sample collection.

Response to reviewers:

Dear reviewer, thank you so much for the comment. It was Dacron swab that was used. Correction has been made accordingly. Thank you once again.

6\) Operating definitions. Penicillin is mentioned here, but in the methods section it is not clear that the isolates were tested for penicillin susceptibility.

Response to reviewers:

Dear reviewer, thank you so much for the comments. Penicillin was unintentionally omitted. The correction have been made as per the comment.

7\) Ehtics and Consent. Please clarify the following sentence. \"At the enrollment visit, all men with urethral discharge (UD) were given written consent diagnosed according to the syndromic treatment guidelines approved in Ethiopia\". It is not clear to this reviewer what \"written consent diagnosed\" means.

Response to reviewers:

Dear reviewer, thank you so much for the comments. The sentence has been clarified per the comment given.

8\) Results. This reviewer does not understand the relevance of the following sentence. \"Observation of the specimens revealed that over 90% of them were profuse /thick discharge (Table-1).

Response to reviewers:

Dear reviewer, thank you so much for the comments. All the urethral discharge specimens were observed visually for checking the clinical manifestation.

9\) Proportion of gonococcal isolates recovered. The sentence \"Compared to culture, the proportion of the identified isolates was higher (75%) when gram stain method was used (Table-2)\" requires editing. It is not possible to isolate NG by gram stain. Please edit sentence as follows \"Compared to culture, the proportion of presumptive gonorrhea-positive samples was higher (75%) by gram stain.

Response to reviewers:

Dear reviewer, thank you so much for the comments. The sentence was not meant to mean that we isolated using gram stain. Since gram stain, in resource limiting setting like ours, can be using to guide the treatment of patients (male), we felt to compare both. We have amended the sentence as commented. Thanks you for your helpful comment.

10\) Figure 1 header. Please change N. gonorrhea to N. gonorrhoeae.

Response to reviewers:

Dear reviewer, thank you so much for the comments. Corrections have been made per the comment.

11\) Conclusion. Please change gonorrhea disease to gonorrhea.

Response to reviewers:

Dear reviewer, thank you so much for the comments. Corrections have been made per the comment.

12\) Conclusion. The authors should add a sentence regarding the limitation of using samples that were collected in 2013-2014. The epidemiology of resistance is probably different now. They can also say that additional studies are warranted to understand the current (2020) epidemiology of antimicrobial resistance in NG in Ethiopia.

Response to reviewers:

Dear reviewer, thank you so much for the comments. The issue has been addressed as per the given comment.
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Click here for additional data file.
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Antimicrobial susceptibility profile of Gonococcal isolates obtained from men presenting with urethral discharge in Addis Ababa, Ethiopia: Implications for national syndromic treatment guideline

PLOS ONE

Dear Mr Dinku,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 21 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

David Gabriel Regan, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The authors have, on the whole, addressed the concerns expressed by the reviewers and the manuscript is much improved. There remain a couple of minor issues that need to be addressed before I can recommend this manuscript for publication;

1\) the frequency columns in tables 1-3 are redundant and should be removed because the identical information in provided in the \'N (%)\' column

2\) the total for Gram stain is missing in Table 2

3\) Table 4 does not contain information regarding multi-drug non-susceptibility as stated on page 9. This information needs to be added to the table or presented in a separate table.

4\) The results presented in Figure 1 are not adequately described in the results on page 9 and the cut-off MIC is not specified so this can not be interpreted. There is also no figure legend for Figure 1, only a figure title.

\[Note: HTML markup is below. Please do not edit.\]

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 2

11 May 2020

The authors have, on the whole, addressed the concerns expressed by the reviewers and the manuscript is much improved. There remain a couple of minor issues that need to be addressed before I can recommend this manuscript for publication;

Response to the Editor:

Dear editor, thank you so much for all the constructive comments. And thank you also for this last opportunity, again, for us to be able to publish our finding. We have tried to address the major issue raised accordingly.

1\) the frequency columns in tables 1-3 are redundant and should be removed because the identical information in provided in the \'N (%)\' column

Response to the Editor:

The correction has been made. The frequency columns in all tables has been removed. Thank you so much for due diligence.

2\) the total for Gram stain is missing in Table 2

Response to the Editor

The correction has been made. The total for gram stain has been added. Thank you so much for due diligence.

3\) Table 4 does not contain information regarding multi-drug non-susceptibility as stated on page 9. This information needs to be added to the table or presented in a separate table.

Response to the Editor:

Correction has been made to the proportion of isolates with non-susceptibility to ciprofloxacin and pencillin and ciprofloxacilin and spectinomycin (In combination) and the reference made to table-4 was removed because it is presented in a narrative form in page 9. In the previous submissions, we added the information in the bottom 2 rows of table -4 and later omitted it because that has caused a confusion to the reviewers as the numbers in these rows did not add up to hundred. Since we only had the combined non-susceptibility for the two agents so did not feel to put the information in a table of its own rather we have indicated in the narrative on page 9.

4\) The results presented in Figure 1 are not adequately described in the results on page 9 and the cut-off MIC is not specified so this cannot be interpreted. There is also no figure legend for Figure 1, only a figure title.

Response to the Editor:

Thank you for the comment. We have attempted to describe the result presented in the figure on page 9 and also have included figure legend as commented on page 9 right immediately after the paragraph where the figure was referenced.
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Dear Dr. Dinku,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

David Gabriel Regan, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I commend the authors on this work and for addressing all issues raised by me and the reviewers.

Reviewers\' comments:
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Dear Dr. Fentaw:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Associate Professor David Gabriel Regan

Academic Editor

PLOS ONE
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